Paradigm Biocapital Advisors significantly increased its stake in Olema Pharmaceuticals (NASDAQ: OLMA) by acquiring 750,000 shares in Q4 2025, bringing its total investment in the company to approximately $122.09 million. This move represents about 4.5% of Paradigm’s assets under management (AUM) as of December 31, 2025, although it remains outside the fund’s top five holdings.

This acquisition is noteworthy as Olema Pharmaceuticals has seen its stock surge 242% over the past year, far outpacing the S&P 500’s 15% gain. The company, focused on developing therapies for women’s cancers, is approaching pivotal Phase 3 trial data and has a robust pipeline supported by over $500 million in cash. This financial cushion positions Olema well for upcoming catalysts, though the recent stock price volatility raises concerns about future performance.

Investors should weigh the potential of Olema’s clinical developments against the backdrop of its rapid stock appreciation, as any disappointing trial results could lead to significant market corrections.

Source: nasdaq.com